Core Insights - Infinimmune has entered a partnership with Merck that could be valued at approximately $838 million in milestone payments for the discovery and development of multiple antibodies targeting undisclosed diseases [1][2]. Group 1: Partnership Details - The agreement includes an undisclosed upfront payment to Infinimmune, with potential milestone payments linked to various drug candidates totaling up to $838 million [2]. - Merck will hold exclusive rights to develop and commercialize the antibody candidates resulting from this collaboration [2]. Group 2: Technology and Focus - Infinimmune will utilize its proprietary platform to screen a large number of human immune cells to identify naturally occurring antibodies, employing AI tools for refinement and enhancement [3]. - The specific disease targets selected by Merck for this partnership have not been disclosed [3]. Group 3: Additional Developments - Apart from the collaboration with Merck, Infinimmune is also working on its own early-stage medicines aimed at treating moderate-to-severe eczema and other immune-related diseases [4].

Company Announcement - Genmab A/S held its Annual General Meeting on March 19, 2026, where the Board of Directors was constituted, appointing Ms. Deirdre P. Connelly as Chair and Ms. Pernille Erenbjerg as Deputy Chair [1] - The company decided to grant 5,213 restricted stock units and 4,485 warrants to employees and subsidiaries [1] Restricted Stock Units - Each restricted stock unit is awarded cost-free and provides a conditional right to receive one share of Genmab A/S, with a fair value of DKK 1,645.00 per unit [2] - The restricted stock units will vest three years after the grant date, subject to specific vesting conditions [3] Warrants - Each warrant is also awarded cost-free, with an exercise price of DKK 1,645.00, allowing the owner to subscribe to one share of nominally DKK 1 [4] - The fair value of each warrant is calculated at DKK 530.62 using the Black-Scholes formula, and they will vest three years after the grant date, expiring at the seventh anniversary of the grant date [5] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases, with over 25 years of experience [6] - The company has a strong late-stage clinical pipeline and has advanced a range of antibody-based therapeutic formats, including bispecific antibodies and antibody-drug conjugates [6] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a presence in North America, Europe, and Asia Pacific [7]

Group 1 - The core announcement corrects the reported share price for transactions involving managerial employees and their closely associated persons, stating the correct price is DKK 1,867.50 instead of DKK 0.00 [1] - The company has disclosed transactions made by managerial employees and their closely associated persons in accordance with market regulations [2] - The announcement includes details about the vesting and net settlement of restricted stock units granted to specific executives as part of their annual bonus achievement [3] Group 2 - Genmab is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases [4] - The company has a strong late-stage clinical pipeline and has advanced a variety of antibody-based therapeutic formats over its 25-year history [4] - Genmab is headquartered in Copenhagen, Denmark, and has a global presence across North America, Europe, and Asia Pacific [5]

Core Insights - Genmab has announced a partnership with Anthropic to enhance its research and development processes through AI capabilities, aiming to bring transformative antibody medicines to patients [1][2] Group 1: Partnership Details - The collaboration will involve designing and deploying custom AI solutions powered by Claude to support Genmab's clinical development priorities [2] - Genmab's teams will utilize Claude for accelerating data processing, analysis, and document generation, which will streamline operational activities and improve consistency in clinical programs [2][4] Group 2: Strategic Goals - This partnership is a significant step in Genmab's transformation towards a more scalable and efficient R&D model aligned with its AI strategy [3] - By reducing manual tasks, the partnership will allow Genmab's teams to focus on high-value scientific and strategic work, ultimately aiming to accelerate the delivery of therapies to patients [3][4] Group 3: Company Background - Genmab is an international biotechnology company focused on improving the lives of cancer patients through innovative antibody medicines, with a strong late-stage clinical pipeline [5][6] - The company has over 25 years of experience in advancing various antibody-based therapeutic formats and has powered eight approved antibody medicines [5]